ATTBF - Abattis Bioceuticals Corp.

Other OTC - Other OTC Delayed Price. Currency in USD

Abattis Bioceuticals Corp.

625 Howe Street
Suite 1200
Vancouver, BC V6C 2T6

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert AbenantePres, CEO & DirectorN/AN/AN/A
Mr. Douglas J. Sorocco LLBAdvisorN/AN/A1971
Mr. Guy P. DancosseAdvisorN/AN/A1944
Mr. Francesco PaoliniCFO & DirectorN/AN/AN/A
Mr. Patrick MitchellChief Operating OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and marketing services. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Corporate Governance

Abattis Bioceuticals Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.